Canadian Body Addresses Shortages Risk

Warns Skyrocketing Transportation Costs Could Cause Supply Chain Disruption

The CGPA and Biosimilars Canada have acknowledged the risk of local shortages amid the coronavirus crisis, after Health Canada advised Canadians that buying more medicine than usual could lead to local supply disruptions.

Canada
The CGPA and Biosimilars Canada are collaborating with international agencies to mitigate potential drug shortages • Source: Shutterstock

Demand-related shortages for specific medicines in Canada due to the coronavirus pandemic have been acknowledged by the Canadian Generic Pharmaceutical Association and Biosimilars Canada, which said they were working with other key industry players to mitigate supply chain disruptions.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Generics

More from Products